HYDROMORPHONE HYDROCHLORIDE (Hydromorphone Hydrochloride) Patent Expiration, LOE Window & CMS Spending

HYDROMORPHONE HYDROCHLORIDE (Hydromorphone Hydrochloride) by Hikma Pharmaceuticals: FDA Orange Book core substance LOE 2043-01-10, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN217812 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-01-10
Last Listed Patent or Exclusivity Date2043-01-10
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 1721.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.